Molsidomine
WikiDoc Resources for Molsidomine |
Articles |
---|
Most recent articles on Molsidomine Most cited articles on Molsidomine |
Media |
Powerpoint slides on Molsidomine |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Molsidomine at Clinical Trials.gov Clinical Trials on Molsidomine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Molsidomine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Molsidomine Discussion groups on Molsidomine Patient Handouts on Molsidomine Directions to Hospitals Treating Molsidomine Risk calculators and risk factors for Molsidomine
|
Healthcare Provider Resources |
Causes & Risk Factors for Molsidomine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Molsidomine is an orally active, long acting vasodilating drug. Molsidomine is metabolized in the liver to the active metabolite SIN-1. SIN-1 is an unstable compound that releases nitric oxide upon decay as the actual vasodilating compound.
Chemistry
Molsidomine as well as SIN-1 are sydnone imines, a class of mesoionic heterocyclic aromatic chemical compounds.
See also
- Nitric oxide
- Nitric oxide releaser
- Vasodilator